

Anna Janecka-WidÅ,a

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6840020/publications.pdf>

Version: 2024-02-01

10
papers

87
citations

1683354

5
h-index

1473754

9
g-index

10
all docs

10
docs citations

10
times ranked

138
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic potential of Akt, pAkt(Ser473) and pAkt(Thr308) immunoreactivity in relation to HPV prevalence in head and neck squamous cell carcinoma patients. <i>Pathology Research and Practice</i> , 2022, 229, 153684.	1.0	4
2	Lack of CD44 and Sox-2 Overexpression as Two Independent Favourable Prognostic Factors in HPV Positive Patients with Oropharyngeal Cancers. <i>Pathobiology</i> , 2022, , 1-9.	1.9	1
3	Assessment of HPV16 infection in patients with laryngeal cancer. <i>Polish Journal of Pathology</i> , 2021, 72, 64-74.	0.1	0
4	Chemopotentiating effects of low-dose fractionated radiation on cisplatin and paclitaxel in cervix cancer cell lines and normal fibroblasts from patients with cervix cancer. <i>DNA Repair</i> , 2021, 103, 103113.	1.3	3
5	Low frequency of HPV positivity in breast tumors among patients from south-central Poland. <i>Infectious Agents and Cancer</i> , 2021, 16, 67.	1.2	3
6	Active HPV infection and its influence on survival in head and neck squamous-cell cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1677-1692.	1.2	22
7	The prevalence of HPV infection in rectal cancer – Report from South – Central Poland (Cracow) Tj ETQq1 1 0.784314 rgBT /Overbo	1.0	9
8	Low-Dose Hypersensitive Response for Residual pATM and γ H2AX Foci in Normal Fibroblasts of Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 756-766.	0.4	8
9	Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 63-73.	1.2	16
10	Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4525-4535.	1.0	21